Cutaneous and Systemic Leishmaniasis Market Study by Pentavalent Antimonials, Antifungal Drugs, and Anti-Leishmanial/Antimicrobial Drugs from 2024 to 2034

<p>The global cutaneous and systemic leishmaniasis market is projected to increase from a valuation of <strong>US$ 368.6 million</strong> in 2024 to <strong>US$ 487.5 million</strong> by the end of 2034. The market has been evaluated to expand at a <strong>CAGR of 2.8%</strong> from 2024 to 2034.</p><table><thead><tr><th>Report Attribute</th><th>Detail</th></tr></thead><tbody><tr><td>Cutaneous and Systemic Leishmaniasis Market Size (2024E)</td><td>US$ 368.6 Million</td></tr><tr><td>Forecasted Market Value (2034F)</td><td>US$ 487.5 Million</td></tr><tr><td>Global Market Growth Rate (2024 to 2034)</td><td>2.8% CAGR</td></tr><tr><td>Canada Market Growth Rate (2024 to 2034)</td><td>3.7% CAGR</td></tr><tr><td>China Market Value (2034F)</td><td>US$ 38 Million</td></tr><tr><td>North America Market Share (2024E)</td><td>50.7%</td></tr><tr><td>East Asia Market Share (2034F)</td><td>18.1%</td></tr><tr><td>Key Companies Profiled</td><td>Gilead Sciences, Inc.; Profounda Pharmaceuticals; Knight Therapeutics Inc.; Janssen Global Services, LLC; Albert David Ltd.; Jubilant Life Sciences Ltd.; Novartis AG; Sanofi; Endo Pharmaceuticals Inc.; Bristol-Myers Squibb Company; United Biotech Pvt. Ltd.</td></tr></tbody></table><p>Country-wise Evaluation</p><table><thead><tr><th>Attribute</th><th>United States</th></tr></thead><tbody><tr><td>Market Value (2024E)</td><td>US$ 162 Million</td></tr><tr><td>Growth Rate (2024 to 2034)</td><td>3.3% CAGR</td></tr><tr><td>Projected Value (2034F)</td><td>US$ 223 Million</td></tr></tbody></table><table><thead><tr><th>Attribute</th><th>China</th></tr></thead><tbody><tr><td>Market Value (2024E)</td><td>US$ 27 Million</td></tr><tr><td>Growth Rate (2024 to 2034)</td><td>3.7% CAGR</td></tr><tr><td>Projected Value (2034F)</td><td>US$ 38 Million</td></tr></tbody></table><p>Category-wise Evaluation</p><table><thead><tr><th>Attribute</th><th>Anti-microbial/Anti-leishmanial</th></tr></thead><tbody><tr><td>Segment Value (2024E)</td><td>US$ 299.3 Million</td></tr><tr><td>Growth Rate (2024 to 2034)</td><td>3% CAGR</td></tr><tr><td>Projected Value (2034F)</td><td>US$ 401.7 Million</td></tr></tbody></table><table><thead><tr><th>Attribute</th><th>Cutaneous Leishmaniasis</th></tr></thead><tbody><tr><td>Segment Value (2024E)</td><td>US$ 277.6 Million</td></tr><tr><td>Growth Rate (2024 to 2034)</td><td>2.7% CAGR</td></tr><tr><td>Projected Value (2034F)</td><td>US$ 363.4 Million</td></tr></tbody></table>

<p>全球皮肤利什曼病与系统性利什曼病市场预计将从2024年的评估价值<Strong>3.686亿美元</Strong>增长至2034年底的<Strong>4.875亿美元</Strong>。该市场预计将在2024年至2034年期间以<Strong>2.8%的复合年增长率（CAGR）</Strong>扩张。</p><table><thead><tr><th>报告属性</th><th>详细信息</th></tr></thead><tbody><tr><td>皮肤利什曼病与系统性利什曼病市场规模（2024E）</td><td>3.686亿美元</td></tr><tr><td>预测市场价值（2034F）</td><td>4.875亿美元</td></tr><tr><td>全球市场增长率（2024至2034年）</td><td>2.8% CAGR</td></tr><tr><td>加拿大市场增长率（2024至2034年）</td><td>3.7% CAGR</td></tr><tr><td>中国市场价值（2034F）</td><td>3.8亿美元</td></tr><tr><td>北美市场份额（2024E）</td><td>50.7%</td></tr><tr><td>东亚市场份额（2034F）</td><td>18.1%</td></tr><tr><td>主要公司简介</td><td>吉利德科学公司（Gilead Sciences, Inc.）、Profounda制药公司、Knight Therapeutics Inc.、强生全球服务公司（Janssen Global Services, LLC）、Albert David Ltd.、Jubilant Life Sciences Ltd.、诺华公司（Novartis AG）、赛诺菲公司（Sanofi）、恩多制药公司（Endo Pharmaceuticals Inc.）、百时美施贵宝公司（Bristol-Myers Squibb Company）、联合生物技术私人有限公司（United Biotech Pvt. Ltd.）</td></tr></tbody></table><p>按国家评估</p><table><thead><tr><th>属性</th><th>美国</th></tr></thead><tbody><tr><td>市场价值（2024E）</td><td>1.62亿美元</td></tr><tr><td>增长率（2024至2034年）</td><td>3.3% CAGR</td></tr><tr><td>预测价值（2034F）</td><td>2.23亿美元</td></tr></tbody></table><table><thead><tr><th>属性</th><th>中国</th></tr></thead><tbody><tr><td>市场价值（2024E）</td><td>0.27亿美元</td></tr><tr><td>增长率（2024至2034年）</td><td>3.7% CAGR</td></tr><tr><td>预测价值（2034F）</td><td>0.38亿美元</td></tr></tbody></table><p>按类别评估</p><table><thead><tr><th>属性</th><th>抗菌/抗利什曼原虫</th></tr></thead><tbody><tr><td>细分市场规模（2024E）</td><td>2.993亿美元</td></tr><tr><td>增长率（2024至2034年）</td><td>3% CAGR</td></tr><tr><td>预测市场规模（2034F）</td><td>4.017亿美元</td></tr></tbody></table><table><thead><tr><th>属性</th><th>皮肤利什曼病</th></tr></thead><tbody><tr><td>细分市场规模（2024E）</td><td>2.776亿美元</td></tr><tr><td>增长率（2024至2034年）</td><td>2.7% CAGR</td></tr><tr><td>预测市场规模（2034F）</td><td>3.634亿美元</td></tr></tbody></table>